• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[低浓度二硫苏糖醇消除单克隆抗CD38对输血相容性检测干扰的评估]

[Evaluation of Low Concentration Dithiothreitol for Negating the Monoclonal Anti-CD38 Interference with Transfusion Compatibility Testing].

作者信息

Song Jie, Chen Li Ying-Hui, Liu Ai-Ping, Wang Shu-Ya, Lyu Xian-Ping

机构信息

Department of Blood Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.

Department of Blood Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China .E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Aug;30(4):1198-1202. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.035.

DOI:10.19746/j.cnki.issn.1009-2137.2022.04.035
PMID:35981384
Abstract

OBJECTIVE

To investigate the effectiveness and safety of low concentration dithiothreitol (DTT) in removing the interference of monoclonal anti-CD38 on transfusion compatibility testing, and develop a reasonable clinical transfusion strategy.

METHODS

The blood type, direct antiglobulin testing (DAT) and antibody screening were tested according to standard methods. Antibody screening cells and donor's red blood cells were treated by DTT 0.2, 0.1, 0.05, 0.02, 0.01 and 0.005 mol/L, and antibody screening and cross-matching of serums after monoclonal anti-CD38 treatment were performed by anti-human globulin card.

RESULTS

The 0.01 mol/L DTT at 37℃ for 30 minutes could remove the effect of monoclonal anti-CD38 on antibody screening and cross-matching, meanwhile retain their effectiveness in detecting anti-K, anti-LW, anti-JMH, anti-Lu, anti-e, anti-Di and anti-Jk alloantibodies. All the 10 patients had no acute or delayed haemolytic transfusion reactions and their routine blood tests showed that the red blood cells transfusion was effective.

CONCLUSION

The 0.01 mol/L DTT is a safe and effective method for removing the interference of monoclonal anti-CD38 with transfusion compatibility testing, while retaining the ability to detect most alloantibodies.

摘要

目的

探讨低浓度二硫苏糖醇(DTT)去除单克隆抗CD38对输血相容性检测干扰的有效性及安全性,制定合理的临床输血策略。

方法

按照标准方法进行血型、直接抗球蛋白试验(DAT)及抗体筛查。用0.2、0.1、0.05、0.02、0.01和0.005 mol/L的DTT处理抗体筛查细胞及供者红细胞,采用抗人球蛋白卡对单克隆抗CD38处理后的血清进行抗体筛查及交叉配血。

结果

0.01 mol/L DTT在37℃孵育30分钟可消除单克隆抗CD38对抗体筛查及交叉配血的影响,同时保留其检测抗-K、抗-LW、抗-JMH、抗-Lu、抗-e、抗-Di和抗-Jk同种抗体的效能。10例患者均未发生急性或迟发性溶血性输血反应,血常规检查显示红细胞输注有效。

结论

0.01 mol/L DTT是一种安全有效的方法,可去除单克隆抗CD38对输血相容性检测的干扰,同时保留检测大多数同种抗体的能力。

相似文献

1
[Evaluation of Low Concentration Dithiothreitol for Negating the Monoclonal Anti-CD38 Interference with Transfusion Compatibility Testing].[低浓度二硫苏糖醇消除单克隆抗CD38对输血相容性检测干扰的评估]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Aug;30(4):1198-1202. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.035.
2
New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing.克服抗 CD38 单克隆抗体在相容性检测中产生干扰的新方法。
Blood Transfus. 2020 Jul;18(4):290-294. doi: 10.2450/2020.0004-20. Epub 2020 Jun 4.
3
Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test.与二硫苏糖醇预处理间接抗球蛋白试验相比,手动聚凝胺法可更好地解决抗 CD38 抗体对血液相容性检测的干扰。
J Clin Lab Anal. 2023 Apr;37(8):e24891. doi: 10.1002/jcla.24891. Epub 2023 May 9.
4
Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.抗 CD38 和抗 CD47 单克隆抗体的临床应用对血型检测和输血治疗及治疗的影响。
Leuk Res. 2022 Nov;122:106953. doi: 10.1016/j.leukres.2022.106953. Epub 2022 Sep 17.
5
Resolving the daratumumab interference with blood compatibility testing.解决达雷妥尤单抗对血液相容性检测的干扰问题。
Transfusion. 2015 Jun;55(6 Pt 2):1545-54. doi: 10.1111/trf.13069. Epub 2015 Mar 12.
6
Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?治疗性抗CD38抗体与Fab片段干扰的缓解:其效果如何?
Transfusion. 2023 Apr;63(4):808-816. doi: 10.1111/trf.17253. Epub 2023 Jan 27.
7
Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).达雷妥尤单抗对间接和直接抗球蛋白试验的不同影响:一种采用0.01 mol/L二硫苏糖醇消除达雷妥尤单抗干扰并保留K抗原性的新方法(大阪法)
Transfusion. 2018 Dec;58(12):3003-3013. doi: 10.1111/trf.14900. Epub 2018 Sep 28.
8
Transfusion management for patients taking an anti-CD38 monoclonal antibody.接受抗CD38单克隆抗体治疗患者的输血管理
Hematol Transfus Cell Ther. 2018 Jan-Mar;40(1):25-29. doi: 10.1016/j.bjhh.2017.09.003. Epub 2017 Nov 26.
9
How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?输血服务部门应如何管理正在接受抗 CD38 和抗 CD47 等疗法治疗的患者,这些疗法已知会干扰红细胞相容性检测?
Transfusion. 2024 Jul;64(7):1217-1222. doi: 10.1111/trf.17880. Epub 2024 May 20.
10
A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells.一种新设计的流式细胞术抗体结合试验有助于评估二硫苏糖醇处理对红细胞上CD38失活的效果。
Vox Sang. 2021 Jul;116(6):725-734. doi: 10.1111/vox.13052. Epub 2020 Dec 13.